Veritas Farms (OTC:VFRM) Stock, Quote.Headers.trade-ideas

Veritas Farms Inc is engaged in producing natural rich-hemp products, using strict natural protocols and materials yielding broad spectrum phytocannabinoid rich hemp oils, distillates and isolates. Its products include Full Spectrum CBD Tincture, Full Spectrum CBD Salve, Full Spectrum CBD Capsules, Full Spectrum CBD Lotion and Others.

Cannabis

News

Penny Stocks

Markets

VFRM

Aeropay and Flyhi entered into a strategic partnership bringing contactless, cashless cannabis delivery payments to businesses and consumers in Denver, CO. The partnership includes integration of Aeropay&#39;s digital and compliant payment solutions into Flyhi&#39;s on-demand home delivery service.

Aeropay And Flyhi Partner To Bring Cashless Cannabis Delivery Payments To Colorado

Veritas Farms, Inc. (OTCQB: VFRM) launched new purpose-built product line designed to target a wide variety of common health conditions, supported with additional dietary supplements.

Veritas Farms Launches New Full Spectrum CBD Functional Product Line

Entrepreneurship

Movers & Shakers

Topics

General

CANSF

INLB

TSX:WLLW

Willow Biosciences Names Barbara Munroe Board Member

Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) has appointed Barbara Munroe to its board of directors.

Cannabis Movers &amp; Shakers: Willow Biosciences, Civilized, Veritas Farms, Item 9, LeafLine Industries

Veritas Farms Inc

Sinclair, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>), the "Company" or "Sinclair," today announced that Sinclair Television Group, Inc. ("STG") and certain affiliated entities have entered into a Transaction Support Agreement (including the attached term sheet and other attachments thereto, the "TSA") with certain of STG's secured creditors (the "Consenting Creditors"), including lenders holding term loans (the "Existing Term Loan Facility") under STG's existing credit facilities (the "Existing Credit Facilities") governed by STG's existing bank credit agreement (the "Existing Credit Agreement") and various holders of STG's outstanding 4.125% Senior Secured Notes due 2030 (the "Existing Secured Notes"), on the principal terms of new money financings and a debt recapitalization (the "Transactions") to strengthen the Company's balance sheet and better position it for long-term growth.

SBGI

Sinclair Announces Debt Recapitalization Agreement with Creditors to Strengthen Financial Position

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) with a Buy and maintains $38 price target.

Price Target

Reiteration

Analyst Ratings

NVCR

HC Wainwright & Co. Reiterates Buy on NovoCure, Maintains $38 Price Target

John Armstrong, Executive Vice President of LPCcommented:
"With a strong foundation laid in 2024, we're entering 2025 with clear momentum and an unwavering focus on growth. The progress we made last year - strengthening our position in core markets and breaking into high-potential segments, sets the stage for what we believe will be transformative advancements. From leveraging synergies with our CMS acquisition to scaling our cutting-edge products like CleanTech, we're poised to redefine what's possible in industrial laser technology. As we look ahead, LPC is committed to delivering value through relentless innovation, improved operational excellence and strategic expansion – we are determined to lead the way in industrial laser solutions."

LASE

Laser Photonics Outlines 2025 Growth Path: Strengthening Core Technologies And Expanding Market Reach

Mawson Infrastructure Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) ("Mawson" or "the Company"), a publicly-traded technology company focused on digital infrastructure platforms for artificial intelligence (AI), high-performance computing (HPC), and digital assets markets, today announced its unaudited business and operational update for December 2024.
<ul>
<li>Digital Colocation Monthly Business Revenue was up 69% Y/Y, to about $4.49 million growing from $2.66 million in December 2023, and up 8% M/M growing from $4.18 million in November 2024.</li>
<li>Total Monthly Revenue up 7% M/M to about $5.26 million from $4.9 million in November 2024.</li>
<li>Monthly Energy Management Business Revenue was up 25% M/M from $0.33 million in November 2024 to $0.41 million in December 2024 and Digital Assets Mining Monthly Business Revenue was $0.36 million.</li>
<li>Total Current Operating Hash Rate (EH) is about 4.98 EH/s (exahashes per second)</li>
<li>Mawson recently signed a new digital colocation customer agreement with a NASDAQ-listed publicly traded company as a customer on January 3, 2025
<ul>
<li>Digital colocation services for 5,880 miners or approximately 20 MW at Mawson's facilities, initial digital colocation customer agreement term is for 12 months, and the parties can extend upon mutual agreement.</li>
<li>Further strengthens Mawson's position as a leading industry provider of digital infrastructure and colocation services in the attractive PJM market, which is North America's largest competitive and deregulated wholesale power market.</li>
<li>Upon completion of this deployment, Mawson expects to operate and manage approximately 41,500 miners.</li>
<li>Combined Total Current Operating Hash Rate (EH) expected to increase to about 5.10 EH/s (includes colocation and self-mining across our facilities).1</li>
</ul>
</li>
<li>Company also has an additional site in Ohio under development which is expected to add an initial 24 MW to the Company's currently operating 129 MW across its sites, growing the Company's total operating capacity to 153 MW, upon completion with further potential expansion of its hashrate.</li>
<li>Mawson supports innovative, agile, efficient, and scalable approaches to AI infrastructure and compute, and invites AI/HPC ecosystem companies to discuss opportunities to collaborate on artificial intelligence, high-performance and accelerated computing solutions.</li>
</ul>

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

Mawson Infrastructure Reports 69% Growth in Colocation Revenue, Secures New Colocation Deal, Projects Hash Rate Increase with Expanded Ohio Facility

CICC analyst Zijie Yang initiates coverage on Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Outperform rating.

Initiation

RBLX

CICC Initiates Coverage On Roblox with Outperform Rating

QUIK

QuickLogic Expands Into Turkiye And UAE With Magenta Distribution Agreement

Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>), a leading oncology testing services company, today announced a multi-year exclusive strategic commercial collaboration that will advance minimal residual disease (MRD) monitoring options for patients with select blood cancers.

ADPT

Adaptive Biotechnologies and NeoGenomics Partner to Enhance MRD Monitoring for Blood Cancer Patients

Announces expansion of metrology suite to support the estimated $400 million critical films market with launch of Iris&#x2122; G2 metrology system

ONTO

Onto Innovation Secures $69M Deal With Leading DRAM Manufacturer And Launches Iris™ G2 Metrology System

Emergent BioSolutions Says It Gained Exclusive Commercial Rights To KLOXXADO (naloxone HCI) Nasal Spray From Hikma Pharmaceuticals

Verastem Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it has exercised early the option to license from GenFleet Therapeutics VS-7375 (also known as GFH375), a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor. In addition, the Company announced preliminary clinical data from the Phase 1 study being conducted by GenFleet in China.

VSTM

Verastem Licenses KRAS G12D Inhibitor VS-7375 Early, Reports Phase 1 Data from GenFleet Study

ZenaTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) (FSE: 49Q) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drones, Drone as a Service, enterprise SaaS and Quantum Computing solutions announces that its subsidiary company ZenaDrone has begun work on an all gas-powered version of the ZenaDrone 1000 drone to enable longer range flight times specifically for US Defense and NATO market use. The company plans to submit a proposal to test this model with the US Air Force through the SBIR (Small Business Innovation Research) Long-Duration Aircraft Program.

Government

Regulations

ZENA

ZenaTech Develops Gas-Powered ZenaDrone 1000 for US Defense and NATO Markets, Plans Proposal to Test Long-Range Drone with US Air Force Under SBIR Program

Deutsche Bank analyst Omotayo Okusanya initiates coverage on Rexford Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>) with a Hold rating and announces Price Target of $40.

REXR

Deutsche Bank Initiates Coverage On Rexford Industrial Realty with Hold Rating, Announces Price Target of $40

Deutsche Bank analyst Omotayo Okusanya initiates coverage on First Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FR#NYSE">FR</a>) with a Hold rating and announces Price Target of $52.

Deutsche Bank Initiates Coverage On First Industrial Realty with Hold Rating, Announces Price Target of $52

Deutsche Bank analyst Omotayo Okusanya initiates coverage on Terreno Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) with a Hold rating and announces Price Target of $60.

TRNO

Deutsche Bank Initiates Coverage On Terreno Realty with Hold Rating, Announces Price Target of $60

Stereotaxis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Oulu University Hospital in Finland have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System from Stereotaxis.

STXS

Stereotaxis' Genesis Robotic System Debuts in Finland, Treats First Patients

Deutsche Bank analyst Omotayo Okusanya initiates coverage on EastGroup Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGP#NYSE">EGP</a>) with a Buy rating and announces Price Target of $180.

Deutsche Bank Initiates Coverage On EastGroup Props with Buy Rating, Announces Price Target of $180

D. Boral Capital analyst Jason Kolbert maintains Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) with a Buy and maintains $6 price target.

ARTL

D. Boral Capital Maintains Buy on Artelo Biosciences, Maintains $6 Price Target

Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) today announced that it has secured $33 million in funding. This funding positions the company to accelerate its growth and deliver on its mission to proliferate industrial autonomous vehicles.

Cyngn Secures $33M Funding to Advance Industrial Autonomous Vehicle Technology

D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) with a Buy and maintains $10 price target.

ANIX

D. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target

Smartkem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTK#NASDAQ">SMTK</a>), which is seeking to change the world of electronics using its disruptive organic thin-film transistors (OTFTs), recapped its key accomplishments for 2024 and set its goals 2025.
 Smartkem Chairman and Chief Executive Officer, Ian Jenks commented, "2024 was a pivotal year for Smartkem. In December, we raised $7.65 million and, together with our collaboration partner, were awarded a $1.1 million grant for a project to develop the world's first rollable, transparent microLED display. We uplisted to Nasdaq, increasing trading liquidity and broadening access to investors. We made significant strides in our plans to commercialize our proprietary semiconductor materials with strategic partnerships and collaborations with industry-leaders. We believe we have strengthened our position as a key player in the market for microLED displays, as well as packaging solutions for advanced computing and AI chips and CMOS for smart sensors. Looking toward 2025, we are focused on achieving qualifications and design wins with existing and new collaborations. We believe our technology will help drive adoption of advanced display and other technologies, with the microLED industry projected to grow from $150 million in 2024 to over $4 billion by 2031.

Comments

Veritas Farms

Veritas Farms (VFRM) Forecast

Veritas Farms (OTC:VFRM) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga